Context Therapeutics is trading at $0.27, up 6.81% in after-hours trading, with no clear company-specific news identified to explain the rise.
- A report published October 14 said Zacks Research downgraded the stock from hold to strong sell. The report said the rating was issued Monday, so it does not establish a fresh after-hours catalyst.
- Broader markets fell after hotter-than-expected September inflation revived rate-hike concerns, but that does not explain Context Therapeutics’ after-hours gain.